Interstitial cells of Cajal in the gut - A gastroenterologist’s point of view

Lucian M Negreanu, Philippe Assor, Bogdan Mateescu, Catalin Cirstoiu

INTRODUCTION

Digestive motility is highly coordinated and consists of local, non-propulsive mixing (segmental) and propulsive (peristaltic) movements. Mixing movements are produced by intrinsic pacemakers generating rhythmic contractions and peristalsis by intrinsic excitatory and inhibitory neural reflex pathways[1,2].

Even in the absence of stimulation, most regions of the gastrointestinal tract can generate some spontaneous electrical and mechanical activity. Recordings made from isolated muscle cells in the gastrointestinal tract show a regular discharge recorded as plateau and slow potentials. These pacemaker potentials are generated by a specialized population of cells, known as interstitial cells of Cajal (ICC)[3].

Together with the enteric nervous system, composed of both the myenteric (inter-muscular) plexus and the submucosal plexus, the ICC plays a major role in gastrointestinal motility[4]. The ICC was firstly described by Cajal SR in 1911[5]. He characterized “interstitial neurons” as “primitive accessory components that could modify smooth muscle contraction, subject themselves to regulation from principal neurons”. Cajal provided detailed pictures of methylene blue-stained networks of interstitial cells, which were described as spindle shaped or stellate cells with long, ramified cell processes and large, oval nuclei with sparse perinuclear cytoplasm, and intercalated between autonomic nerve endings and smooth muscle cells[6].

ICC constitutes networks that are widely distributed within the submucosal, intra-muscular and inter-muscular layers of the gastrointestinal tract from the lower esophagus to the internal anal sphincter. These cells are defined by the expression of the CD117 (c-kit) protein which is a membrane receptor with tyrosine kinase activity[7,8].

In the past decade, knowledge of the role of ICC in the digestive physiology and pathology has progressed. In this review, we highlight some of these advances which could have clinical impact either in pathogenesis or treatment.

ESOPHAGUS

Achalasia

Achalasia is characterized by relaxation failure of lower
esophageal sphincter (LES) and lack of peristaltic contraction of esophageal body[1]. The etiology of this disorder is unknown and may be “idiopathic” or secondary to malignancy (local invasion or a paraneoplastic manifestation).

In primary or idiopathic achalasia, the failure of deglutitive inhibition is responsible for aperistalsis. This dysfunction is due to a loss of inhibitory nerves and progressive degeneration of ganglion cells containing vasoactive intestinal peptide (VIP) and nitric oxide (NO). Hypertensive LES is thought to result from a combination of the lack of tonic inhibitory nitricergic influence and an unopposed cholinergic activity.

The mechanism of inflammatory process responsible for these alterations is unclear. It is suggested to be an autoimmune disorder induced by a viral or food antigen in a patient genetically predisposed to the disease[8,9]. ICC involvement in achalasia is debated[10,11].

Electron microscope studies of muscle coat of LES in seven patients with achalasia showed that muscle wall components (nerve endings, smooth muscle cells, ICC and connective tissue) were modified. ICC ultrastructure was altered, namely clear cytoplasm, fewer mitochondria, and scarce smooth endoplasmic reticulum. A reduced number of contacts between nerves and ICC were reported. Specific changes in smooth muscle cells were also documented, whereas the nerve endings had a normal ultrastructure. Alterations in older patients were more pronounced[12]. Since the LES components specifically altered in achalasia are the nerve endings and ICC, they are regarded as principally responsible for abnormal motility[13].

Achalasia is uncommon among pediatric population and some authors consider it as a different entity. Rare familial forms, combining early onset achalasia, alacrimia, ACTH insensitivity and dysautonomia, are known as Allgrove’s syndrome or “four A” syndrome. Allgrove’s syndrome is inherited in an autosomal recessive mode and may express in adulthood. Massive loss of neural elements and neuronal NO synthase as well as a marked fibrotic process of the muscle layers of the cardia have been observed in this syndrome[13]. ICC in cardia was also markedly decreased or absent while ICC (and neural structures) were preserved in pylorus[13].

Gastro-esophageal reflux disease (GERD)
GERD is a highly prevalent condition. Typical symptoms of heartburn and acid regurgitation are encountered in 15%-20% of the general population[14].

GERD represents the most common cause of esophagitis that may be complicated with esophageal ulcers, peptic stenosis and Barrett’s esophagus, which carries a high risk of esophageal adenocarcinoma[14].

The role of the ICC in inhibitory transmission in the LES is still discussed.

In W/W, mutant mice (lack of ICC) LOS pressure was lower than wild-type mice but a normal swallow still induced LOS relaxation, arguing against the role of ICC in inhibitory transmission[15]. Another study demonstrated that in W/W, animals, cholinergic and nitrogic neurotransmission is greatly reduced pleading for the role of ICC in mediating neural inputs[16]. However enteric neurons, varicose processes, and the ability to release neurotransmitters are not reduced, and smooth muscle cells demonstrate responsiveness to exogenous transmitters[16].

Loss of ICC during development or in pathologic conditions would significantly compromise the ability of GI muscles to generate typical motor reflexes[17].

Esophagitis itself may be at the origin of an alteration of normal function of the Cajal cells: in advanced stages of GERD, inflammatory changes in the esophageal wall will also involve the ICC. That way, the more severe the esophagitis, the more severe is the ICC impairment. This destruction leads to loss of effective contraction of esophagus, maintaining reflux and thus aggravating the symptoms[19].

STOMACH
Gastroparesis
Delayed gastric emptying can be secondary to muscular, neural, humoral causes or use of anticholinergic and opiates medicines. In the absence of an identified cause, gastroparesis is termed as idiopathic[19]. Clinical features of gastroparesis are frequently indistinguishable from true mechanical obstruction and severity of symptoms is variable. Most patients present with early satiety, nausea, and abdominal pain. In some cases, symptoms can be highly incapacitating: chronic abdominal pain and vomiting leading to dehydration, electrolyte imbalance, nutritional impairment and weight loss[20,21].

ICC is involved in regulation of gastric emptying by generating slow waves.

A decrease in ICC density ranged from 60% to 100% depending on the area investigated was demonstrated in histologic studies of stomach of type 1 diabetic patients[8]. The number of immunopositive cells for c-kit was significantly decreased in the corpus and antrum of the gastroparesis patients compared with control tissues[21]. The loss of intra muscular ICC and associated nerves in the gastric fundus could explain the low basal gastric tone and increased compliance of the stomach. The hypomotility of the antrum can also be explained by the absence of slow wave generation by the ICC[21,22].

Infantile hypertrophic pyloric stenosis
This is a congenital disorder characterized by functional gastric-outlet obstruction. Dysfunction of pyloric inhibition has been implicated in the pathophysiology of hypertrophic pyloric stenosis. Normal inhibition process is mediated by peptidergic and NO enteric nerves and also may involve ICC. Although myenteric neurons appear normal, those innervating the circular-muscle layer of the pyloric sphincter lack NO synthetase[23]. In children with hypertrophic pyloric stenosis, there was a significant decrease in the number of ICC[22,23]. The following observations were made using electron microscopy in gastric specimens from patients with pyloric stenosis versus normal controls[24]. Muscle cells were primarily in a
proliferative phase and exhibited very few gap junctions between smooth muscle cells or ICC: (1) Near absence of nerve fibers containing large granular vesicles in the circular muscle layer; (2) Fewer nerve cell bodies in the myenteric plexus and lower total number of ganglia; (3) Decreased number of ICC. These findings may plead for a role of ICC in the pathogenesis.

SMALL INTESTINE AND COLON

**Idiopathic chronic intestinal pseudo-obstruction (CIIP)**
CIIP is characterized by defective gastrointestinal propulsion together with symptoms and signs of bowel obstruction in the absence of any lesions or mechanical obstacle[33]. CIIP is regarded as a neuropathy, myopathy or both[26,27].

A possible role played by the ICC is demonstrated by the alterations in ICC network reported in patients with CIIP. Electron microscopy and immunohistochemistry studies showed a decreased number of ICCs along with structural abnormalities such as loss of processes and damaged intracellular cytoskeleton and organelles[20].

**Slow transit constipation (STC)**
This is a very prevalent motility problem, but its mechanisms are unclear. Studies found that ICC density in the colon of patients with constipation was significantly decreased compared with those of normal patients[28]. Expression of c-kit mRNA and c-kit protein was significantly decreased in the colon of STC, suggesting that the c-kit signal pathway may play an important role in ICC reduction in STC[30-32].

Since slow-transit constipation is secondary to problems with the ENS, ICC, or smooth muscle cells, replacement of the missing or defective cells would be an attractive way of treatment[31]. Growing precursors of the defective cells from stem cells should be easy, but the distribution of the cells to their proper locations is still problematic[11,32]. For the moment this is a promise of genetic treatment.

TUMORS OF GASTROINTESTINAL TRACT

**Gastrointestinal stromal tumors (GISTs)**
GISTs have been recognized as a biologically distinctive tumor type, different from smooth muscle and neural tumors of the gastrointestinal tract. They constitute the majority of gastrointestinal mesenchymal tumors[33].

GISTs originate from the ICC. Their origin from the ICC has been proven by their immunophenotypic (CD117 positive) and ultrastructural resemblance and also by the presence of an embryonic smooth muscle myosin similar to the one present in the ICC[31-34] (Table 1). Approximately 80% of GISTs also express CD34.

Annual incidence of clinically detected new cases of GISTs in the United States has increased to 5000-6000 per year due to better diagnosis, and incidence is rising. Uncommonly, GISTs arise in families, and in these patients germline mutations of c-kit have been identified particularly in exons 11 and 13. A diffuse hyperplasia of the ICC, which is regarded as a pre-neoplastic lesion is noted in these patients[33]. The patients with exon 11 mutations develop cutaneous mastocytosis with or without cutaneous hyperpigmentation, but those with exon 13 mutations do not have these features[33,34]. The tumors under 3 cm in diameter are mostly benign, but all GISTs have a malignant potential[35].

The majority of GISTs occurs in the stomach (60%-70%), small intestine (20%-30%) and only 10% or less in the esophagus, colon and rectum, and they affect mainly middle aged patients. Similar tumors, sometimes known as extra-gastrointestinal stromal tumors (E-GIST), may arise in the omentum, mesentery, or retroperitoneum and at least one case of pancreatic tumor was described[37,58]. The presence of ICC in normal pancreas was demonstrated recently[39].

The symptoms may vary from none or slight abdominal discomfort to brisk gastrointestinal hemorrhage, perforation or obstruction.

Imatinib mesylate, a synthetic tyrosine kinase inhibitor developed for the use in the management of interferon resistant chronic myeloid leukemia (CML), was shown to be effective against a number of other tyrosine kinases including c-kit and platelet derived growth factor (PDGF) and now it is considered to be the drug of choice for metastatic and inoperable GISTs[33,34].

**CONCLUSION**

Knowledge on the role of ICC in gastrointestinal disorders is increasing. However, with the exception of GIST’s, no major breakthrough has been made in treatment. Further studies may provide new treatments.

| Tumor | Positive immunohistochemical staining |
|-------|--------------------------------------|
| GIST  | CD 117                               |
|       | CD 34                                |
| Malignant GIST | Ki 67                          |
| Smooth muscle tumor | Smooth muscle actin |
| Schwannoma | S100                               |
| Glomus tumor | Smooth muscle actin |
|         | Vimentin                             |

**REFERENCES**

1 Stevens RJ, Publicover NG, Smith TK. Induction and organization of Ca2+ waves by enteric neural reflexes. *Nature* 1999; 399: 62-66
2 Wood JD. Mixing and moving in the gut. *Gut* 1999; 45: 333-334
3 Ward SM. Interstitial cells of Cajal in enteric neurotransmission. *Gut* 2000; 47 Suppl 4: iv40-iv43; discussion iv52
4 Takaki M. Gut pacemaker cells: the interstitial cells of Cajal (ICC). *J Smooth Muscle Res* 2003; 39: 137-161
5 Cajal SR. Histology of the nervous system of man and animal.
vertebrates (translated by N Swanson and LW Swanson), New York: Oxford University Press, 1995: 891-942

6 Long QL, Fang DC, Shi HT, Luo YH. Gastro-electric dysrhythm and lack of gastric interstitial cells of cajal. World J Gastroenterol 2004; 10: 1227-1230

7 Sifrim D, Janssens J, Vantrappen G. Failing deglutitive inhibition in primary esophageal motility disorders. Gastroenterology 1994; 106: 875-882

8 Robertson CS, Martin BA, Atkinson M. Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut 1993; 34: 594-329

9 Metman EH, Lagasse JP, Pic P, Picon L, Danquechin Dorval E, Goudeau A. [Varicella and primary achalasia of the lower esophageal sphincter] Gastroenterol Clin Biol 1996; 20: 1138-1139

10 Ward SM, Morris G, Reese L, Wang XY, Sanders KM. Interstitial cells of Cajal mediate enteric inhibitory neurotransmission in the lower esophageal and pyloric sphincters. Gastroenterology 1998; 115: 314-329

11 Sanders KM, Ward SM, Daniel EE. ICC in neurotransmission: hard to swallow a lack of involvement. Gastroenterology 2002; 122: 1185-1186; author reply 1186-1187

12 Faussone-Pellegrini MS, Cortesini C. The muscle coat of the lower esophageal sphincter in patients with achalasia and hypertensive sphincter. An electron microscopic study. J Submicrosc Cytol 1985; 17: 673-685

13 Metman EH, Debbabi S, Negreau L. Troubles moteurs de l’oesophage, Encyclopédie medico-chirurgicale. Elsevier 2006; 1: 1-19

14 Richter JE. Gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol 2007; 21: 609-631

15 Dickens EJ, Edwards FR, Hirst GD. Selective knockout of intramuscular interstitial cells reveals their role in the generation of slow waves in mouse stomach. J Physiol 2001; 531: 827-833

16 Ward SM, Beckett WA, Wang X, Baker F, Khoyi M, Sanders KM. Interstitial cells of Cajal mediate cholinergetic neurotransmission from enteric motor neurons. J Neurosci 2000; 20: 1393-1403

17 Ward SM, Sanders KM. Physiology and pathophysiology of the interstitial cell of Cajal: from bench to bedside. I. Functional development and plasticity of interstitial cells of Cajal networks. Am J Physiol Gastrointest Liver Physiol 2001; 281: G662-G611

18 Shafik A, El-Sibai O, Shafik I, Shafik A. Electroesophagogram in gastroesophageal reflux disease with a new theory on the pathogenesis of its electric changes. BMC Surg 2004; 4: 13

19 Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum RW. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg 2005; 9: 102-108

20 Hirst GD, Edwards FR. Role of interstitial cells of Cajal in the control of gastric motility. J Pharmacol Sci 2004; 96: 1-10

21 Ibba Manneschi L, Pacini S, Corsani L, Bechi P, Faussone-Pellegrini MS. Interstitial cells of Cajal in the human stomach: distribution and relationship with enteric innervation. Histol Histopathol 2004; 19: 1153-1164

22 Ordog T, Redelman D, Horvath VJ, Miller LJ, Horowitz B, Sanders KM. Quantitative analysis by flow cytometry of interstitial cells of Cajal, pacemakers, and mediators of neurotransmission in the gastrointestinal tract. Cytometry A 2004; 62: 139-149

23 Vanderwinden JM, Rumessen JJ. Interstitial cells of Cajal in human gut and gastrointestinal disease. Microsc Res Tech 1999; 47: 344-360

24 Langer JC, Berezin I, Daniel EE. Hypertrophic pyloric stenosis: ultrastructural abnormalities of enteric nerves and the interstitial cells of Cajal. J Pediatr Surg 1995; 30: 1535-1543

25 De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut 2004; 53: 1549-1552

26 Coulie B, Camilleri M. Intestinal pseudo-obstruction. Annu Rev Med 1999; 50: 37-55

27 De Giorgio R, Guerini S, Barbara G, Cremon C, Stanghellini V, Corinaldesi R. New insights into human enteric neuropathies. Neurogastroenterol Motil 2004; 16 Suppl 1: 143-147

28 Feldstein AE, Miller SM, El-Youssef M, Roederig D, Lindor NM, Burgart LJ, Szurszewski JH, Farruggia G. Chronic intestinal pseudo-obstruction associated with altered interstitial cells of cajal networks. J Pediatr Gastroenterol Nutr 2003; 36: 492-497

29 Basilisco G, Gebbia C, Peracchi M, Velio P, Conte D, Bresolin N, Nobile-Orazio E. Cerebellar degeneration and hearing loss in a patient with idiopathic myenteric ganglionitis. Eur J Gastroenterol Hepatol 2005; 17: 449-452

30 Tong WD, Liu BH, Zhang LY, Xiong RP, Liu P, Zhang SB. Expression of c-kit messenger ribonucleic acid and c-kit protein in sigmoid colon of patients with slow transit constipation. Int J Colorectal Dis 2005; 20: 363-367

31 Schiller LR. New and emerging treatment options for chronic constipation. Rev Gastroenterol Disord 2004; 4 Suppl 2: S43-S51

32 Rao SS. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003; 32: 659-683

33 D’Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2010; 17: 44-56

34 de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 2003; 9: 13-19

35 Hwang JH, Kimmey MB. The incidental upper gastrointestinal subepithelial mass. Gastroenterology 2004; 126: 501-507

36 Ando N, Goto H, Niwa Y, Hirooka Y, Ohmiya N, Nagasaka T, Hayakawa T. The diagnosis of GI stromal tumors with chemical analysis. Gastrointest Endosc 2002; 55: 37-43

37 Nakagawa M, Akasaka Y, Kanai T, Yamashita T, Kuroda M, Takayama H, Miyazawa N. Extragastrointestinal stromal tumor of the greater omentum: case report and review of the literature. Hepatogastroenterology 2003; 50: 691-695

38 Yamaura K, Kato K, Miyazawa M, Hata Y, Muramatsu A, Miya K, Koide N. Stromal tumor of the pancreas with expression of c-kit protein: report of a case. J Gastroenterol Hepatol 2004; 19: 467-470

39 Popescu LM, Hinescu ME, Ionescu N, Ciontea SM, Cretoiu D, Ardelean C. Interstitial cells of Cajal in pancreas. J Cell Mol Med 2005; 9: 169-190

S- Editor Li DL - L Editor Alpinii GD - E Editor Ma WH